U.S. cardiovascular device sector threatened by tariffs, according to GlobalData report
The US tariffs on metals like steel, aluminum, and copper have had a significant impact on cardiovascular device manufacturers, affecting both production costs and market growth.
### Challenges for Cardiovascular Device Manufacturers
The 50% tariffs on steel and aluminum have disrupted access to and affordability of critical high-grade metals needed to meet stringent medical device safety and regulatory standards. This has increased production costs significantly and tightened already narrow profit margins for manufacturers.
Manufacturers face higher expenses and delays as they navigate longer supplier onboarding cycles, risk assessments, and compliance checks while seeking alternative suppliers domestically or in new geographies. With steel, aluminum, and now copper under steep tariffs, material costs for cardiovascular devices—which often rely on these metals—have risen, pushing up the overall manufacturing expenses.
The tariffs create uncertainty and volatility that hamper long-term planning and delay investments in production capacity. This is critical for cardiovascular device makers whose industry emphasizes precision and consistency. Some companies may have to absorb costs and reduce margins or pass increased prices downstream to buyers, potentially affecting the pricing of cardiovascular implants and devices.
### Market Growth and Healthcare System Effects
Raised manufacturing costs could constrain supply chain efficiency and lead to potential shortages or delayed deliveries of cardiovascular devices, impacting patient care particularly in smaller or rural healthcare settings. Healthcare providers must absorb increased device costs, which may reduce purchasing power and slow adoption of newer cardiovascular technologies.
While hospitals do not appear to be stockpiling equipment in response to price hikes yet, sustained tariffs may influence procurement strategies and overall device availability. The overall healthcare ecosystem, including payers and supply chain partners, faces financial pressure that could slow the growth trajectory of the cardiovascular device market due to cost inflation and supply disruptions.
In summary, the US tariffs on key metals have led to higher production costs, supply chain challenges, and pricing pressures for cardiovascular device manufacturers. These factors contribute to a more complex operating environment, potentially slowing market growth and access to cardiovascular devices, and increasing costs for healthcare providers and patients in the US.
Notably, the US cardiovascular device market is worth approximately 34.5 billion USD and is growing at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2034. However, the impact of tariffs on cardiovascular device companies could decrease sales and growth in the US.
Expert analysts like Beauchamp suggest that without a more concrete policy on tariffs, cardiovascular device manufacturers may face ongoing uncertainty. Many cardiovascular device companies rely on manufacturing outside the US to address demand. The current American administration's policy on tariffs remains unstable, causing manufacturers to continuously change internal forecasts and production plans.
References: [1] Medical Device Manufacturing News [2] Medical Plastics Insights [3] Tariffs and Cardiovascular Device Manufacturers [4] The Impact of Tariffs on Cardiovascular Device Prices
- The rise in material costs for cardiovascular devices, due to tariffs on steel, aluminum, and copper, is significantly increasing overall manufacturing expenses for the industry.
- The steep tariffs on medical plastics could potentially lead to increased production costs, supply chain challenges, and pricing pressures for cardiovascular device manufacturers.
- The uncertainty and volatility created by tariffs on critical metals used in medical devices may affect the long-term health of the industry and slow the growth trajectory of the cardiovascular device market.
- The increase in device costs due to tariffs may impose financial pressure on healthcare providers, potentially reducing purchasing power and slowing the adoption of newer cardiovascular technologies.
